Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atomoxetine + trazodone for obstructive sleep apnea
IRCT20220607055095N1Phase 3Completed
- Sponsor
- Tehran University of Medical Sciences
- Start
- Jul 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of atomoxetine and trazodone in obstructive sleep apnea hypopnea syndrome (OSAHS) (2 arms), sponsored by Tehran University of Medical Sciences. Primary endpoints: Sleep quality improvement and reduction in apnea/hypopnea attacks, Number of respiratory arrests and 1 more. Started Jul 2022; status: completed.
02
Drugs
atomoxetinetrazodone
03
Conditions
obstructive sleep apnea hypopnea syndrome (OSAHS)
Beyond the preview
Go deeper on IRCT20220607055095N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20220607055095N1.